Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Other Non Operating Income (2016 - 2025)

United Therapeutics (UTHR) has disclosed Other Non Operating Income for 17 consecutive years, with $47.2 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 1915.38% to $47.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.9 million through Dec 2025, up 743.1% year-over-year, with the annual reading at $48.9 million for FY2025, 743.1% up from the prior year.
  • Other Non Operating Income hit $47.2 million in Q4 2025 for United Therapeutics, up from $6.1 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $97.2 million in Q1 2021 to a low of -$51.8 million in Q2 2022.
  • Historically, Other Non Operating Income has averaged $2.1 million across 5 years, with a median of -$1.6 million in 2023.
  • Biggest five-year swings in Other Non Operating Income: crashed 23400.0% in 2021 and later surged 1915.38% in 2025.
  • Year by year, Other Non Operating Income stood at -$28.8 million in 2021, then soared by 81.6% to -$5.3 million in 2022, then skyrocketed by 88.68% to -$600000.0 in 2023, then crashed by 333.33% to -$2.6 million in 2024, then soared by 1915.38% to $47.2 million in 2025.
  • Business Quant data shows Other Non Operating Income for UTHR at $47.2 million in Q4 2025, $6.1 million in Q3 2025, and -$100000.0 in Q2 2025.